Multi-Modal Connected Workflow for Cardiac Safety Assessment of Drugs Using hiPSC-Derived Cardiomyocytes Session 2
Pharmaceutical compounds need to undergo safety assessment screening. These in vitro frontline screening assays should be multi-parametric, scalable and mechanistic enabling a high degree of predictivity and specificity. Increasingly, cardiomyocytes are being utilized for the safety assessment of pharmaceutical compounds as they represent a highly relevant model system and can potentially provide broad information regarding electrical, mechanical, metabolic and structural liabilities.
In this webinar, we will discuss a connected workflow using human iPSC-derived cardiomyocytes (hiPSC-CMs) for microelectrode-based measurements (including viability and contraction, live-cell imaging, mitochondrial toxicity, and cell metabolism) as a frontline screening assay for safety assessment of pharmaceutical drug compounds.
In this webinar, we will discuss a connected workflow using human iPSC-derived cardiomyocytes (hiPSC-CMs) for microelectrode-based measurements (including viability and contraction, live-cell imaging, mitochondrial toxicity, and cell metabolism) as a frontline screening assay for safety assessment of pharmaceutical drug compounds.
Attend this webinar to:
- Learn about technologies for studying viability, contractility, electrophysiology, and metabolism of cardiomyocytes
- Gain a deeper understanding of in vitro cardiotoxicity screening strategy
- How to extract relevant information on adverse effects of drug from the same cell preparation
Speakers
Ryan McGarrigle
Research Scientist, Agilent Technologies
Xiaoyu Zhang
Senior Research Scientist, Agilent Technologies
